
Novocure (NVCR) Stock Forecast & Price Target
Novocure (NVCR) Analyst Ratings
Bulls say
NovoCure Ltd has demonstrated a positive financial outlook, highlighted by a 4% sequential revenue increase to $174.4 million in 4Q25, along with an 8% year-over-year growth to a total of $655.4 million for the full year 2025. Notably, the growth in prescriptions for Optune Lua in non-small cell lung cancer (NSCLC) by 8% signifies increasing adoption of its products, while the receipt of national reimbursement in Spain is anticipated to further enhance revenue streams in 2026. Additionally, the company expects ongoing US growth driven by improved sales dynamics and contributions from clinical trials, positioning itself favorably within the oncology treatment market.
Bears say
NovoCure Ltd is experiencing a downward revision in revenue estimates, with the projected revenue for glioblastoma reduced to $690 million from $702 million and total revenue adjusted down to $711.3 million from $738.9 million for 2026. Key risks contributing to this negative outlook include poor sales adoption of Optune devices, potential clinical failures of Tumor Treating Fields technologies across various indications, and increased competition from other treatment options. Additionally, there are concerns regarding the efficacy of clinical programs, potential safety signals, and regulatory challenges that may impact the company's future financial performance.
This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.
Novocure (NVCR) Analyst Forecast & Price Prediction
Start investing in Novocure (NVCR)
Order type
Buy in
Order amount
Est. shares
0 shares